500 patients66,097 observations150 daysLIVE
Two cohorts, clusters or histories on the same canvas: trajectories, biology, and what worked in each.

Compare

Synthetic demo data
Build a cohort to compare
Mean lived trajectory
Observed days only; faint verticals are dosing days (infusion on day 1 of each 14-day cycle).
A · EC-01 · Delayed loss of response (45)B · minResponseProbability 0.65 (176)
State and risk
ABA − B
Patients45176-131
Mean treatment day130129+1
Strong responders0%100%-100%
Discontinuation risk ≥ 70%0%0%0%
At risk0%0%0%
Tolerance deteriorating27%32%-5%
GI unstable0%0%0%
Response today4181-40
GI burden today1716+1
Toxicity today13130
Adherence85%92%-7%
Quality of life5877-19
Biology
Share of each cohort in every biology segment the learning layer uses.
SegmentABA − B
FUT2 non-secretor64%22%+42 pp
IL6 high-expression variant56%21%+35 pp
Poor metabolizer33%16%+17 pp
Low butyrate capacity73%1%+72 pp
Low microbial diversity87%6%+81 pp
Baseline state S147%7%0 pp
Cluster EC-03 (high response / high intolerance)0%0%0 pp
Adherence < 60%0%0%0 pp
What worked in each
Improved share among accepted instances inside each cohort. Monitoring actions excluded.
A · EC-01 · Delayed loss of response
BR-03 Behavioural Recommendation7
71%
AD-05 Adherence Support5
40%
B · minResponseProbability 0.65
No accepted actions.
LLIFE OS insight · A · EC-01 · Delayed loss of response
grounded · add an LLM key for prose

EC-01 · Delayed loss of response: 45 patients, mean day 130. 27% have deteriorating tolerance, 0% unstable GI, 0% carry ≥60% discontinuation risk; mean GI 17, adherence 85%. Dominant clusters: EC-01 100%.

Shared biology: Low microbial diversity 87%, Low butyrate capacity 73%, FUT2 non-secretor 64%, IL6 high-expression variant 56%, Poor metabolizer 33%. Dietary detractors: fat in 89%, lactose in 84%, histamine in 67%.

What worked: BR-03 improved 71% of 7; what did not: AD-05 improved only 40% of 5. By biology: BR-03 works best in Low butyrate capacity (80%) and worst in Low microbial diversity (67%); AD-05 works best in Low microbial diversity (40%) and worst in IL6 high-expression variant (25%).

No learned rules apply yet; run learning after the first campaign results.

LLIFE OS insight · B · minResponseProbability 0.65
grounded · add an LLM key for prose

minResponseProbability 0.65: 176 patients, mean day 129. 32% have deteriorating tolerance, 0% unstable GI, 0% carry ≥60% discontinuation risk; mean GI 16, adherence 92%. Dominant clusters: SR 68%, EC-02 24%, MR 7%.

Shared biology: no dominant biology. Dietary detractors: lactose in 63%, alcohol in 37%, histamine in 27%.

No accepted actions in this cohort yet.

No learned rules apply yet; run learning after the first campaign results.